Lochhamer Str. 11
Tel: 49-89-85 65 29-00
Fax: 49-89-85 65 29-20
221 articles with MediGene AG
Conference call and webcast, August 07, 2019 at 3:00 pm CET, 9:00 am EST
Medigene AG announced its participation at the following upcoming investor conferences:
Medigene AG: Interim analysis from ongoing Phase I/II clinical trial with DC vaccines in AML patients presented at EHA
Medigene AG announced that clinical data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene's DC vaccine for the treatment of acute myeloid leukemia was presented during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
Medigene AG announces that two scientific posters with preclinical data on an HA-1-specific T-cell receptor and a NY-ESO-1/LAGE-1-specific T-cell receptor were shown on 21 May 2019 during the CIMT Annual Meeting in Mainz.
Martinsried/Munich Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reports on the Company's Annual General Meeting which was held in Munich.
Medigene AG: Medigene announces clinical trial agreement for HA-1 TCR immunotherapy MDG1021 with University of Leiden
Medigene AG announced that it entered into a Clinical Trial Agreement with the Leiden University Medical Center, the Netherlands, to conduct a Phase I clinical trial with Medigene's T cell receptor modified T cell therapy MDG1021 targeting the HA-1 antigen.
Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019
Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene's DC vaccine during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
Conference call and webcast (in English) today, May 14, 2019 at 3:00 pm CET / 9:00 am EST
Medigene AG: bluebird presents preclinical data of first TCR candidate from Medigene collaboration. Start clinical development 2020
Medigene AG announced that the Company's strategic partner bluebird bio, Inc. (NASDAQ:BLUE), USA, at its analyst day presentation, will present preclinical data of the first therapeutic T cell receptor (TCR) candidate resulting from the research and development partnership with Medigene.
Medigene AG announced its participation at the following upcoming scientific, business development and investor conferences
Medigene AG: Medigene presented data on favorable safety pattern of PRAME-specific TCR on neuronal cells at 2019 ASGCT Meeting
Functional 2D and 3D in vitro assays using neuronal cells derived from iPSCs to assess the potential risk of TCR-mediated neurotoxicity
Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets
Medigene AG announced its participation at the following upcoming networking and scientific conferences
Medigene AG: Medigene presented selective killing of tumor cells by PRAME TCR-transduced T cells at AACR
3D co-cultured healthy cells survive in method for evaluation of TCR efficacy and toxicity
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
High-throughput assessment of neoantigens recognized by both CD8+ and CD4+ T cells presented at Immuno-Oncology Summit Europe
Medigene AG (FSE: MDG1, Prime Standard, SDAX) today publishes preliminary financial results for the financial year 2018.
Medigene AG announced that researchers of the Company will present a poster at the 2019 American Association for Cancer Research Annual Meeting.
Medigene AG: Medigene announces dosing of first patient in Phase I/II trial with TCR therapy MDG1011 for various blood cancers
Medigene AG announced that it has dosed the first patient in its first-in-human clinical trial with its TCR therapy candidate MDG1011.
Medigene AG: European Patent covering TCR library suitable for the development of neoantigen-specific TCRs
Medigene AG reported that the European Patent Office intends to grant a European Patent for the patent application EP3303591A1 covering a T cell receptor building block library that is suitable for rapid reconstruction and testing of newly discovered TCR sequences against classical antigens as well as neoantigens.